Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Discovery of ALG-093989, a Highly Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancers

Friday, November 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of ALG-093989, a new small molecule PD-L1 inhibitor. This compound shows high potency and is designed to be orally bioavailable, which could improve treatment adherence among cancer patients. The development represents a significant advancement in cancer therapy options.
Price reaction · baseline $18.6925 (2023-11-03T18:45:00.000Z) · hit during market hours · clean, no other ALGS news in the window
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discovery of a highly potent PD-L1 inhibitor
  • Orally bioavailable formulation enhances patient compliance
  • Potential for treating various cancers

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-093989?

ALG-093989 is a newly discovered small molecule PD-L1 inhibitor for cancer treatment.

How does ALG-093989 improve patient compliance?

Its oral bioavailability allows for easier administration compared to injectable therapies.

What type of cancers can ALG-093989 treat?

ALG-093989 has potential applications in treating various types of cancers.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-093989 cancer treatment PD-L1 oral bioavailability small molecule
Last updated: Nov 3, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →